Biora Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Harry Stylli
- Full Time Employees
- 124
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4330 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Jun 19, 2020
- CIK
- 0001580063
- Website
- progenity.com
- Similar Companies
- Business
- Biora Therapeutics, Inc. (Nasdaq: PROG) develops oral biotherapeutics using proprietary targeted delivery platforms designed for gastrointestinal diseases. The company offers the NaviCap platform, which enables oral delivery of biologics including peptides, antibodies, and other macromolecules via microbots that navigate through the stomach and release payloads in the intestines; the SOMA platform, utilizing self-orienting hydrogel mm-scale pills for delayed and controlled release of therapeutics in the small intestine; and the I.P. SCAP platform for oral systemic delivery of biologics achieving subcutaneous-like bioavailability. These platforms support applications in ulcerative colitis, celiac disease, inflammatory bowel disease, and other GI disorders, with pipeline candidates including BIO-11006 (NaviCap-based anti-TL1A antibody for ulcerative colitis), ORB-001 (SOMA-based therapeutic for celiac disease), and others targeting oral delivery of GLP-1 agonists and additional biologics. Biora Therapeutics operates in the biotechnology sector, primarily serving pharmaceutical partners and patients in the United States and Europe; the company was founded in 2016 and is headquartered in San Diego, California. In recent developments, Biora Therapeutics rebranded from Progenity, Inc. to reflect its strategic focus on oral delivery technologies following a 2022 corporate reorganization and name change; the company completed a reverse merger with Airoc Health in 2023, expanded its manufacturing capabilities with a new GMP facility in 2024, and announced positive Phase 1 clinical data for its NaviCap platform in late 2024, alongside a strategic partnership with a major pharmaceutical company for co-development of oral biologics in 2025.
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms
Progenity to Become Biora Therapeutics as it Completes Transformation
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Should You Invest in These Penny Stocks Next Month? 3 to Watch
Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO'22
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
Top Reddit Penny Stocks That Investors Are Watching Right Now
3 Penny Stocks Climbing During Today's Trading Session
These 4 Penny Stocks Exploded Today, Here's Why
Here's 3 Trending Penny Stocks to Add to Your Watchlist in February
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
5 Top Penny Stocks To Buy Now According To Reddit